← All trials
NCT02398994
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2015
- Primary completion
- Mar 1, 2016
- Completion date
- Mar 1, 2016
- First posted
- —
- Last posted
- —
- Enrollment
- 2
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- University of LondonLead sponsor
- University of ManchesterCollaborator
- Cardiff UniversityCollaborator
- NHS LothianCollaborator
- University of OxfordCollaborator
- University of BirminghamCollaborator
- University of BristolCollaborator
- University of LiverpoolCollaborator
- University of NottinghamCollaborator
- Moorgreen Hospital, SouthamptonCollaborator
- Salford Royal Foundation NHS TrustCollaborator
- University of LondonCollaborator
- University of LondonOverall official - principal investigator
- Newcastle UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.